|
1
|
Szutowicz A, Kwiatkowski J and Angielski
S: Lipogenetic and glycolytic enzyme activities in carcinoma and
nonmalignant diseases of the human breast. Br J Cancer. 39:681–687.
1979. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hennipman A, Smits J, van Oirschot B, van
Houwelingen JC, Rijksen G, Neyt JP, Van Unnik JA and Staal GE:
Glycolytic enzymes in breast cancer, benign breast disease and
normal breast tissue. Tumour Biol. 8:251–263. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Warburg O: On the origin of cancer cells.
Science. 123:309–314. 1956. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Drake B and Cook GJ: Positron emission
tomography computed tomography in oncology. Br J Hosp Med (Lond).
72:631–637. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Robey IF, Stephen RM, Brown KS, Baggett
BK, Gatenby RA and Gillies RJ: Regulation of the Warburg effect in
early-passage breast cancer cells. Neoplasia. 10:745–756.
2008.PubMed/NCBI
|
|
6
|
Gottlieb E and Tomlinson IP: Mitochondrial
tumour suppressors: a genetic and biochemical update. Nat Rev
Cancer. 5:857–866. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Guppy M, Leedman P, Zu X and Russell V:
Contribution by different fuels and metabolic pathways to the total
ATP turnover of proliferating MCF-7 breast cancer cells. Biochem J.
364:309–315. 2002.PubMed/NCBI
|
|
8
|
Dalgard CL, Lu H, Mohyeldin A and Verma A:
Endogenous 2-oxoacids differentially regulate expression of oxygen
sensors. Biochem J. 380:419–424. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Papandreou I, Cairns RA, Fontana L, Lim AL
and Denko NC: HIF-1 mediates adaptation to hypoxia by actively
downregulating mitochondrial oxygen consumption. Cell Metab.
3:187–197. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Macheda ML, Rogers S and Best JD:
Molecular and cellular regulation of glucose transporter (GLUT)
proteins in cancer. J Cell Physiol. 202:654–662. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
El-Bacha T, de Freitas MS and Sola-Penna
M: Cellular distribution of phosphofructokinase activity and
implications to metabolic regulation in human breast cancer. Mol
Genet Metab. 79:294–299. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Vora S, Halper JP and Knowles DM:
Alterations in the activity and isozymic profile of human
phosphofructokinase during malignant transformation in vivo and in
vitro: transformation- and progression-linked discriminants of
malignancy. Cancer Res. 45:2993–3001. 1985.
|
|
13
|
Dunaway GA: A review of animal
phosphofructokinase isozymes with an emphasis on their
physiological role. Mol Cell Biochem. 52:75–91. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zancan P, Sola-Penna M, Furtado CM and Da
Silva D: Differential expression of phosphofructokinase-1 isoforms
correlates with the glycolytic efficiency of breast cancer cells.
Mol Genet Metab. 100:372–378. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Šmerc A, Sodja E and Legiša M:
Posttranslational modification of 6-phosphofructo-1-kinase as an
important feature of cancer metabolism. PLoS One.
6:e196452011.PubMed/NCBI
|
|
16
|
Shonk CE and Boxer GE: Enzyme patterns in
human tissues. I. Methods for the determination of glycolytic
enzymes. Cancer Res. 24:709–721. 1964.PubMed/NCBI
|
|
17
|
Coelho WS, Costa KC and Sola-Penna M:
Serotonin stimulates mouse skeletal muscle 6-phosphofructo-1-kinase
through tyrosine-phosphorylation of the enzyme altering its
intracellular localization. Mol Genet Metab. 92:364–370. 2007.
View Article : Google Scholar
|
|
18
|
Gatenby RA and Gillies RJ: Why do cancers
have high aerobic glycolysis? Nat Rev Cancer. 4:891–899. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hennipman A, van Oirschot BA, Smits J,
Rijksen G and Staal GE: Glycolytic enzyme activities in breast
cancer metastases. Tumour Biol. 9:241–248. 1988. View Article : Google Scholar
|
|
20
|
Hennipman A, van Oirschot BA, Smits J,
Rijksen G and Staal GE: Heterogeneity of glycolytic enzyme activity
and isozyme composition of pyruvate kinase in breast cancer. Tumour
Biol. 9:178–189. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hron WT and Menahan LA: Age-related
changes in activities of hepatic phosphofructokinase, pyruvate
kinase and pyruvate dehydrogenase in liver and adipose tissue of
the swiss albino mouse. Enzyme. 30:83–88. 1983.
|
|
22
|
Steffen V, Gordillo E, Castano A, Caño J
and Machado A: Age-dependent changes in the activity and
isoenzymatic pattern of the phosphofructokinase in different areas
of the central nervous systems. Neurosci Lett. 125:15–18. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jia SS and Liu YH: Effects of estrogen on
the expression of phosphofructokinase muscle-specific isoform in
genioglossus of chronic intermittent hypoxia rats. Zhonghua Kou
Qiang Yi Xue Za Zhi. 45:627–630. 2010.(In Chinese).
|
|
24
|
Augoff K and Grabowski K: Significance of
lactate dehydrogenase measurements in diagnosis of malignancies.
Pol Merkur Lekarski. 17:644–647. 2004.(In Polish).
|
|
25
|
Sánchez-Martínez C and Aragon JJ: Analysis
of phosphofructokinase subunits and isozymes in ascites tumor cells
and its original tissue, murine mammary gland. FEBS Lett.
409:86–90. 1997.PubMed/NCBI
|
|
26
|
Moon JS, Kim HE, Koh E, Park SH, Jin WJ,
Park BW, Park SW and Kim KS: Krüppel-like factor 4 (KLF4) activates
the transcription of the gene for the platelet isoform of
phosphofructokinase (PFKP) in breast cancer. J Biol Chem.
286:23808–23816. 2011.
|
